Table 1.
Demographic and clinical data of patients with COVID-19.
| Pre–Omicron VOC era (n = 106) | Omicron VOC era (n = 113) | |
|---|---|---|
| Demographic data | ||
| Male, n (%) | 54 (50.9%) | 70 (61.9%) |
| Age at presentation, months, median (IQR) | 2.9 (1.3–7.6) | 5.3 (1.3–8.4) |
| 0–4 years, n | 65 | 54 |
| 5–11 years, n | 23 | 53 |
| 12–17 years, n | 18 | 6 |
| Vaccinated against SARS-CoV-2, n | 1 | 0 |
| Multiplex PCR, n, positive for non-SARS-CoV-2/obtained | 5/15 | 2/16 |
| Treatment and outcome during clinical course | ||
| Antibiotics, n | 3 | 4 |
| Remdesivir, n | 4 | 1 |
| Casirivimab/Imdevimab, n | 0 | 0 |
| Sotrovimab, n | 0 | 0 |
| Dexamethasone, n | 4 | 0 |
| ICU admission, n | 0 | 0 |
| High-flow nasal cannula, n | 0 | 0 |
| Mechanical ventilation, n | 0 | 0 |
| Severity | ||
| Non-severe, n (%) | 104 (98.1%) | 112 (99.2%) |
| Severe, n (%) | 2 (1.9%) | 1 (0.9%) |
| Critical, n (%) | 0 | 0 |
| Multisystem inflammatory syndrome in children, n | 0 | 0 |
| Deatha, n | 0 | 0 |
COVID-19, coronavirus disease 2019; VOC, variant of concern; IQR, interquartile range; PCR, polymerase chain reaction.
a
Complication up to 6 weeks after hospital visit.